Insight into Druckenmiller's Latest 13F Filings and Portfolio Adjustments. Stanley Druckenmiller (Trades, Portfolio), the ...

Ascendis Pharma (ASND) has released an update. Ascendis Pharma has released its unaudited financial results for the period ending September 30, ...

Ascendis Pharma (ASND) has released an update. Ascendis Pharma reported a revenue of €57.8 million in Q3 2024, driven by product launches and ...

YORVIPATH launching in U.S. with product availability expected mid-January 2025; ex-U.S. YORVIPATH revenue of €8.5 million in ...

LOS ANGELES, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Nova LifeStyle, Inc. (NASDAQ: NVFY) ("Nova LifeStyle” or the "Company”) today ...

Metsera has brought in over $500m in funding in just seven months as it looks to enter the competitive weight loss arena.

Ascendis Pharma (ASND) is scheduled to announce Q3 earnings results on Thursday, November 14th, after market close. The ...

The group was led by Casdin Capital, which surged 16 percent last month, according to an investor. This puts its share class that invests only in public securities up more than 40 percent for the year ...

Adults with hypoparathyroidism treated with TransCon PTH in the phase 3 PaTHway open-label trial extension demonstrated ...

European equities traded in the US as American depositary receipts were moving higher late Monday morning, rising 0.35% to 1,339.76 on the S&P Europe Select ADR Index. From continental Europe, the ...

Royalty Pharma's Q3 results show growth driven by strong portfolio performance and acquisitions. See why we recommend a buy ...